Usefulness of
Adolescent
Adult
Aged
Aged, 80 and over
Female
Fluorodeoxyglucose F18
Humans
Male
Middle Aged
Neoplasm Grading
Neoplasm Recurrence, Local
/ diagnostic imaging
Neuroendocrine Tumors
/ diagnostic imaging
Pancreatic Neoplasms
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
Predictive Value of Tests
Radiopharmaceuticals
Retrospective Studies
18F-FDG-PET/CT
neuroendocrine tumor
pancreas
Journal
Journal of hepato-biliary-pancreatic sciences
ISSN: 1868-6982
Titre abrégé: J Hepatobiliary Pancreat Sci
Pays: Japan
ID NLM: 101528587
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
13
09
2019
revised:
09
02
2020
accepted:
15
03
2020
pubmed:
21
3
2020
medline:
17
7
2021
entrez:
21
3
2020
Statut:
ppublish
Résumé
Although We retrospectively compared demographics and pathological features between Seventy-two patients were enrolled. The avidity of
Sections du résumé
BACKGROUND
BACKGROUND
Although
METHODS
METHODS
We retrospectively compared demographics and pathological features between
RESULTS
RESULTS
Seventy-two patients were enrolled.
CONCLUSIONS
CONCLUSIONS
The avidity of
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
414-420Informations de copyright
© 2020 Japanese Society of Hepato-Biliary-Pancreatic Surgery.
Références
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-72.
Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, Takano K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol. 2015;50:58-64.
Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
Farwell MD, Pryma DA, Mankoff DA. PET/CT imaging in cancer: current applications and future directions. Cancer. 2014;120:3433-45.
Barrington SF, Mikhaeel NG. When should FDG-PET be used in the modern management of lymphoma? Br J Haematol. 2014;164:315-28.
Okano K, Kakinoki K, Akamoto S, Hagiike M, Usuki H, Yamamoto Y, et al. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer. World J Gastroenterol. 2011;17:231-5.
Abdulrezzak U, Kurt YK, Kula M, Tutus A. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors. Nucl Med Commun. 2016;37:874-81.
Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, et al. Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42:241-51.
Han S, Kim YJ, Woo S, Suh CH, Lee JJ. Prognostic value of volumetric parameters of pretreatment 18F-FDG PET/CT in esophageal cancer: a systematic review and meta-analysis. Clin Nucl Med. 2018;43:887-94.
Kornaczewski Jackson ER, Pointon OP, Bohmer R, Burgess JR. Utility of FDG-PET imaging for risk stratification of pancreatic neuroendocrine tumors in MEN1. J Clin Endocrinol Metab. 2017;102:1926-33.
Ezziddin S, Adler L, Sabet A, Pöppel TD, Grabellus F, Yüce A, et al. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system. J Nucl Med. 2014;55:1260-6.
Masui T, Doi R, Ito T, Kami K, Ogawa K, Harada D, et al. Diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to the World Health Organization classification. Oncol Lett. 2010;1:155-9.
Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25:79-83.
Matsumoto T, Okabe H, Yamashita YI, Yusa T, Itoyama R, Nakao Y, et al. Clinical role of fludeoxyglucose (18F) positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with pancreatic neuroendocrine tumors. Surg Today. 2019;49:21-6.
Rinzivillo M, Partelli S, Prosperi D, Capurso G, Pizzichini P, Iannicelli E, et al. Clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography in the diagnostic algorithm of advanced entero-pancreatic neuroendocrine neoplasms. Oncologist. 2018;23:186-92.
Bucau M, Laurent-Bellue A, Poté N, Hentic O, Cros J, Mikail N, et al. 18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation. Neuroendocrinology. 2018;106:274-82.
Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, et al. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE. Eur J Nucl Med Mol Imaging. 2017;44:490-9.
Satoh K, Sadowski SM, Dieckmann W, Quezado M, Nilubol N, Kebebew E, et al. 18F-FDG PET/CT volumetric parameters are associated with tumor grade and metastasis in pancreatic neuroendocrine tumors in von Hippel-Lindau disease. Ann Surg Oncol. 2016;23:714-21.
Durán HJ, Ielpo B, Díaz E, Fabra I, Caruso R, Malavé L, et al. Predictive prognostic value of local and distant recurrence of F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to World Health Organization classifications (2004, 2010). Case series study. Int J Surg. 2016;29:176-82.
Squires MH 3rd, Volkan Adsay N, Schuster DM, Russell MC, Cardona K, Delman KA, et al. Octreoscan versus FDG-PET for neuroendocrine tumor staging: a biological approach. Ann Surg Oncol. 2015;22:2295-301.
Tomimaru Y, Eguchi H, Tatsumi M, Kim T, Hama N, Wada H, et al. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors. Surgery. 2015;157:269-76.
Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul JL, et al. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation. J Nucl Med. 2014;55:1786-90.
Kim HS, Choi JY, Choi DW, Lim HY, Lee JH, Hong SP, et al. Prognostic value of volume-based metabolic parameters measured by (18)F-FDG PET/CT of pancreatic neuroendocrine tumors. Nucl Med Mol Imaging. 2014;48:180-6.
Luo G, Liu Z, Guo M, Jin K, Xiao Z, Liu L, et al. (18)F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. Int J Oncol. 2014;45:1531-6.
Kedia P, Gaidhane M, Kahaleh M. Technical advances in endoscopic ultrasound (EUS)-guided tissue acquisition for pancreatic cancers: how can we get the best results with EUS-guided fine needle aspiration? Clin Endosc. 2013;46:552-623.
Hwang HS, Kim Y, An S, Kim SJ, Kim JY, Kim SY, et al. Grading by the Ki-67 labeling index of endoscopic ultrasound-guided fine needle aspiration biopsy specimens of pancreatic neuroendocrine tumors can be underestimated. Pancreas. 2018;47:1296-303.